225Ac-PSMA I&T Composition for Stable Low-Toxicity Radionuclide Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic castration-resistant prostate cancer (mCRPC) using 177Lu-PSMA mAb J591 and 225Ac-PSMA TAT suffer from high hematological and salivary gland toxicity, limiting their widespread application, while 177Lu-PRLT fails to affect some patients, necessitating a treatment with lower toxicity profiles.
Innovation Solution
A radiopharmaceutical composition comprising actinium-225 (225Ac)-PSMA I&T, formulated with ascorbic acid and hydrochloric acid, offering improved shelf-life stability and low toxicity profiles, with radiochemical purity and stability maintained for up to 120 hours, suitable for targeted radionuclide therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 177Lu-PSMA mAb J591 or 225Ac-PSMA TAT is used for targeted radionuclide therapy, then therapeutic effect is improved, but hematological and salivary gland toxicity increases
Solution Approach 1:
The patent changes the chemical parameters of the radiopharmaceutical formulation by using small molecule inhibitors (PSMA-617, PSMA I&T) instead of monoclonal antibodies, and optimizes the radiolabeling conditions with actinium-225 to achieve high radiochemical purity (>95%) and stability. This parameter change reduces the molecular size and improves tumor penetration while maintaining therapeutic efficacy and reducing toxicity.
Solution Approach 2:
The patent employs small molecule inhibitors that are rapidly cleared from the body compared to monoclonal antibodies, reducing prolonged exposure to healthy tissues. The short-lived actinium-225 (half-life of 10 days) delivers therapeutic radiation quickly and decays, minimizing long-term toxicity accumulation in salivary glands and hematological systems.
2Reliability
If monoclonal antibodies are used for PSMA targeting, then therapeutic effect is achieved, but clearance from circulation is slow causing grade 4 hematotoxicity
Solution Approach 1:
The patent fundamentally changes the molecular size parameter by replacing large monoclonal antibodies (150 kDa) with small molecule inhibitors (less than 1 kDa). This parameter change results in rapid renal clearance of the small molecules from circulation, reducing exposure time to healthy hematological tissues and preventing grade 4 hematotoxicity while maintaining effective tumor targeting.
3Object-affected harmful factors
If small molecule inhibitors of PSMA are used instead of mAb, then hematotoxicity is reduced, but radiochemical stability must be maintained for extended shelf life
Solution Approach 1:
The patent introduces DOTA chelators as intermediary molecules that strongly bind actinium-225 to the PSMA inhibitor ligands. This intermediary chelating mechanism ensures high radiochemical stability (>95% purity) and prevents radiolysis during extended storage (up to 120 hours at room temperature), while the small molecule structure maintains rapid clearance and low hematotoxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 225Ac-PSMA I&T composition provides effective targeted radionuclide therapy with reduced toxicity, demonstrating better therapeutic effects and fewer adverse effects than monoclonal antibody treatments, with radiochemical stability and purity ensuring safe administration.
Implementation Method 1
a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy
Data Source
AI summary
The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.